Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 1,794 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intervention 2 - Sham Treatment Clear all

Conditions: Alzheimer Disease
Interventions: cycloastragenol, placebo (for cycloastragenol); Dietary Supplement
Lead sponsor: Chippewa Valley Eye Clinic; Other
Eligibility: 50 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Eau Claire, Wisconsin

Conditions: Prader-Willi Syndrome
Interventions: Oxytocin, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 1 Week to 6 Months
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Ischemic Stroke
Interventions: NCS-01; Biological
Lead sponsor: NC Medial Research Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Substance Abuse, Suicide, Depression
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS), sham rTMS; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tobacco Use Disorder
Interventions: Neutral or active cigarette cues; Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Laryngomalacia, Acid Reflux, Stridor
Interventions: ranitidine or famotidine, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: Up to 4 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Skin Aging, Skin Wrinkling
Interventions: PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, saline solution (placebo); Drug
Lead sponsor: Kalpna Kay Durairaj, MD, FACS; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Pasadena, California

Conditions: COVID-19
Interventions: nirmatrelvir, ritonavir, placebo for nirmatrelvir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 67
States / cities: Mesa, Arizona • Phoenix, Arizona • Surprise, Arizona + 47 more

Conditions: Major Depressive Disorder (MDD), Suicidal Ideation, Hospitalization in Children
Interventions: Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham; Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 14 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Huntington's Disease
Interventions: intra-striatal rAAV5-miHTT, Imitation (sham) surgery; Genetic · Other
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 12
States / cities: Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 9 more

Conditions: Chronic Pain
Interventions: Operator Role Real TMS, Receiver Role Real TMS, Operator Role Sham TMS, Receiver Role Sham TMS, All Participants Operator Role; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Pain
Interventions: Hydrocodone/acetaminophen, Placebo, Ibuprofen, Lorazepam, Lidocaine; Drug
Lead sponsor: Elizabeth Micks; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Malignant Melanoma
Interventions: Pembrolizumab, Lenvatinib, Placebo for lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Santa Monica, California + 13 more

Conditions: Diabetes Mellitus Type 2
Interventions: Inspiratory Muscle Strength Training (IMST), Sham Training; Device
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 14 Years to 40 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Trauma, Hemorrhage
Interventions: Calcium Gluconate, Vasopressin, saline placebo; Drug
Lead sponsor: Jason Sperry; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Chandler, Arizona • Tucson, Arizona • Little Rock, Arkansas + 13 more

Conditions: Opioid Use Disorder
Interventions: Exablate Model 4000 Type 2.0/2.1; Device
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Rectal Microbicides
Interventions: Tenofovir 1% gel, 2% N-9 gel, HEC Placebo gel; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Birmingham, Alabama • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Liraglutide Pen Injector, Saline Injections; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Traumatic Brain Injury, Aging Related Cognitive Decline
Interventions: Active tDCS and Cognitive Training Intervention, Sham tDCS and Cognitive Training Intervention; Combination Product
Lead sponsor: Minneapolis Veterans Affairs Medical Center; Federal
Eligibility: 65 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Anxiety, Pain, Burnout, Professional
Interventions: Lavender aromatherapy sticker; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: HIV Infections
Interventions: Placebo tablets; Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Placebo, AZD0780; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 26
States / cities: Inglewood, California • Northridge, California • Pomona, California + 20 more

Conditions: Alcohol Drinking, Alcohol Use Disorder
Interventions: Ketone Ester "(R)-3-hydroxybutyl (R)-3-hydroxybutyrate", Isocaloric dextrose placebo, Alcohol drinks; Dietary Supplement · Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Marijuana Use Disorder
Interventions: Inactive Marijuana (0% THC), Low THC marijuana (1.8 %THC), High THC marijuana (3.9% THC); Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Telomerase Activator and Retinal Amyloid

Intranasal Oxytocin for Infants With Prader-Willi Syndrome

A Study of NCS-01 in Patients With Acute Ischemic Stroke

Functional Connectivity Alterations in Suicidal Patients Among Opioid Users

Effect of Smoking Exposure on Smoking Relapse Following Brief Abstinence - 2

In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?

Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation

Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease

Effects of Transcranial Magnetic Stimulation (TMS) and Stimulus Controllability on Pain Perception

Hydrocodone For Pain Control in First Trimester Surgical Abortion

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

Effects of High-Resistance Inspiratory Muscle Strength Training on Cardiorenal and Vascular Function in Youth and Young Adults With Type 2 Diabetes

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD)

Rectal Safety and Acceptability Study of Tenofovir 1% Gel

The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes

Remote Stimulation and Training to Advance Recovery From TBI in Seniors

Relaxing Environment to Lower Anxiety During Onabotulinum Toxin Chemodenervation of the Bladder

B/F/TAF Ease of Swallowability Trial

A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure

Ketone Ester Intervention in Alcohol Use Disorder

Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks